Double-Blind, parallel-group comparison, investigators initiated phase II clinical trial of IDEC-C2B8 (Rituximab) in patients with Systemic Sclerosis

Trial Profile

Double-Blind, parallel-group comparison, investigators initiated phase II clinical trial of IDEC-C2B8 (Rituximab) in patients with Systemic Sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Rituximab (Primary)
  • Indications Systemic scleroderma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jan 2018 Last checked against University Hospital Medical Information Network - Japan record.
    • 18 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 29 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top